PTX.ASX: June 2026 Quarterly Update and Appendix 4C

June 2026 Quarterly Update and Appendix 4C

Stock	Prescient Therapeutics Ltd (PTX.ASX)
Release Time	27 Jul 2026, 12:36 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Prescient Therapeutics Q2 2026 Update: Clinical Progress and Financials

Key Points

Cash balance of $9.03 million at quarter end
28 patients enrolled in PTX-100 Phase 2a trial
Dr. Rosalind Wilson appointed as Chief Medical Officer
Engaged with key haematology experts in Europe
Online investor briefing scheduled for August 3rd

Full Summary

Prescient Therapeutics Ltd. released its June 2026 quarterly update, highlighting significant progress in its clinical programs and financial status. The company reported a cash balance of $9.03 million as of June 30, 2026, an increase from $7.93 million at the end of March 2026. The Phase 2a trial for PTX-100 saw a notable increase in patient enrolment, reaching 28 patients by the end of the quarter. Additionally, Prescient announced the appointment of Dr. Rosalind Wilson as Chief Medical Officer, effective July 13, 2026. The company also engaged with key haematology experts in Europe, attending the European Hematology Association (EHA) 2026 Congress in Stockholm. An online investor briefing is scheduled for August 3, 2026, to discuss these developments further.